MORGAN STANLEY PLC/CALL/VIATRIS/16/1/21.03.25 Share Price

Warrant

DE000MG2EX36

Market Closed - Börse Stuttgart 11:39:53 07/06/2024 pm IST
0.47 EUR 0.00% Intraday chart for MORGAN STANLEY PLC/CALL/VIATRIS/16/1/21.03.25
Current month-2.08%
1 month-41.98%
Date Price Change
07/24/07 0.47 0.00%
06/24/06 0.47 -2.08%
05/24/05 0.48 -2.04%
04/24/04 0.49 0.00%
03/24/03 0.49 +2.08%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 11:39 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VIATRIS INC.
Issuer Morgan Stanley
WKN MG2EX3
ISINDE000MG2EX36
Date issued 16/04/2024
Strike 16 $
Maturity 21/03/2025 (285 Days)
Parity 1 : 1
Emission price 0.36
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.86
Lowest since issue 0.45
Delta0.24x
Omega 4.599
Premium57.98x
Gearing19.39x
Moneyness 0.6544
Difference Strike 5.53 $
Difference Strike %+34.56%
Spread 0.06
Spread %11.32%
Theoretical value 0.5000
Implied Volatility 50.86 %
Total Loss Probability 87.39 %
Intrinsic value 0.000000
Present value 0.5000
Break even 16.54 €
Theta-0.02x
Vega0.03x
Rho0.01x

Company Profile

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 30 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Sector
-
More about the company

Ratings for Viatris Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Viatris Inc.

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
10.47 USD
Average target price
12.4 USD
Spread / Average Target
+18.40%
Consensus